en · de · es · fr · pt
cjc-1295-notes.peptides4962.com › Data › Identity And Naming History — Background and Details

Identity And Naming History — Background and Details

By Editorial Desk · published 2026-04-18 · last reviewed 2026-05-19 · Data

The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-05-19. Anything still debated is marked as such rather than presented as settled.

Identity and Naming History

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideGHRH analog, not a steroid
Backbone length29 amino acidsBased on GRF(1-29)
SubstitutionsFour positionsD-Ala2, Gln8, Ala15, Leu27
AppearanceWhite to off-white powderTypical lyophilized research material
Common synonymsModified GRF(1-29)Usage varies between sources

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Related pages on this site

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Background from the literature

== Clinical significance == Impaired NO production is involved in the pathogenesis of several diseases such as hypertension, preeclampsia, diabetes mellitus, obesity, erectile dysfunction, and migraine. In this regard, a large number of studies showed that polymorphisms in NOS3 gene affect the susceptibility to these diseases. Although NOS3 is a highly polymorphic gene, three genetic polymorphisms in this gene have been widely studied: the single nucleotide polymorphisms (SNPs) g.-786T>C (where "g." denotes genomic change which results in a Glu298Asp change in the coded protein), located in NOS3 promoter and in exon 7, respectively, and the variable number of tandem repeats (VNTR) characterized by 27 bp repeat in intron 4. The C allele for the g.-786T>C polymorphism, which results in reduced eNOS expression and NO production, was associated with increased risk for hypertension, preeclampsia, diabetic nephropathy, and retinopathy, migraine, and erectile dysfunction. The presence of 'Asp' allele for the Glu298Asp polymorphism reduces eNOS activity, and was associated with higher susceptibility to hypertension, preeclampsia, diabetes mellitus, migraine, and erectile dysfunction. The VNTR in intron 4 affects eNOS expression, and the susceptibility to hypertension, preeclampsia, obesity, and diabetes mellitus. Growing evidence supports the association of diseases with NOS3 haplotypes (combination of alleles in close proximity, within a DNA block). This approach may be more informative than the analysis of genetic polymorphisms one by one.

== History == In 1998, the University of Michigan formed a commission to create a vision for the future of the life sciences at the university. In response to the commission's recommendations, in 1999, the Regents of the University of Michigan unanimously approved the construction of the Life Sciences Institute, noting that "the creation of a life sciences institute will eliminate the structural barriers to a shared research and learning experience that will be valuable for both basic and applied research." Initial funding of $100 million was provided for the creation of wet lab space, in addition to the $130 million for the endowment and startup costs. The first faculty members moved into the building and opened their labs in September 2003, and the institute opened in May 2004. That same year, the institute's first two research cores opened, supporting high-throughput screening and structural biology research : the Center for Structural Biology and the Center for Chemical Genomics. The cryo-electron microscopy facility opened in 2009, expanding the institute's structural biology capabilities. In 2018, with support from the U-M Biosciences Initiative, the institute began expanding the cryo-EM program and also launched its Natural Products Discovery Core. In 2021, the building that houses the institute was renamed Mary Sue Coleman Hall, in honor of President Emerita Mary Sue Coleman.

Flashing Flashing LEDs are used as attention seeking indicators without requiring external electronics. Flashing LEDs resemble standard LEDs but they contain an integrated voltage regulator and a multivibrator circuit that causes the LED to flash with a typical period of one second. In diffused lens LEDs, this circuit is visible as a small black dot. Most flashing LEDs emit light of one color, but more sophisticated devices can flash between multiple colors and even fade through a color sequence using RGB color mixing. Flashing SMD LEDs in the 0805 and other size formats have been available since early 2019. Flickering Simple electronic circuits integrated into the LED package have been around since at least 2011 which produce a random LED intensity pattern reminiscent of a flickering candle. Reverse engineering in 2024 has suggested that some flickering LEDs with automatic sleep and wake modes might be using an integrated 8-bit microcontroller for such functionally. Sometimes a flickering effect might happen due to an electric malfunction. Bi-color Bi-color LEDs contain two different LED emitters in one case. There are two types of these. One type consists of two dies connected to the same two leads antiparallel to each other. Current flow in one direction emits one color, and current in the opposite direction emits the other color. The other type consists of two dies with separate leads for both dies and another lead for common anode or cathode so that they can be controlled independently. The most common bi-color combination is red/traditional green.

== Biological role == In general, aminopeptidases play an important role in the metabolism of both proteins and peptides. Aminopeptidases in the gastrointestinal tract, such as APN and APA, are essential for the digestion of dietary proteins. They facilitate the absorption and utilization of amino acids by cleaving them from the N-terminus of peptides. These enzymes also play a role in the metabolism of bioactive peptides, including hormones and growth factors. By regulating the levels of these peptides, aminopeptidases contribute to homeostasis and physiological process modulation.

Sources: en.wikipedia.org

Further detail

== Structure of penicillin binding protein 3 == Penicillin binding protein 3 is important for bacteria wall synthesis and is a main target in β-lactam antibiotics. It is a two-domain protein containing a C-terminal transpeptidase linked to an extended N-terminal domain. This protein is similar to other class B PBP’s since it contains an α-helical subdomain or “head” domain towards the N-terminus. The N-terminal domain’s function is still not known but it is thought it serves to position the transpeptidase domain away from the inner membrane as part of a multienzyme complex involved in cell wall biosynthesis.

=== Discovery of peroxisome === Serendipity followed de Duve for another major discovery. After the confirmation of lysosome, de Duve's team was troubled by the presence (in the rat liver cell fraction) of the enzyme urate oxidase. De Duve thought it was not a lysosome because it is not an acid hydrolase, typical of lysosomal enzymes; still, it had similar distribution as the enzyme acid phosphatase. Further, in 1960 he found other enzymes (such as catalase and D-amino acid oxidase), that were similarly distributed in the cell fraction—and it was then thought that these were mitochondrial enzymes. (W. Bernhard and C. Rouillier had described such extra-mitochondrial organelles as microbodies, and believed that they were precursors to mitochondria.) de Duve noted the three enzymes exhibited similar chemical properties and were similar to those of other peroxide-producing oxidases. De Duve was skeptical of referring to the new-found enzymes as microbodies because, as he noted, "too little is known of their enzyme complement and of their role in the physiology of the liver cells to substantiate a proposal at the present time". He suggested that these enzymes belonged to the same cell organelle, but one different from previously known organelles. But, as strong evidences were still lacking, he did not publish his hypothesis. In 1955 his team demonstrated similar cell fractions with same biochemical properties from the ciliated protozoan Tetrahymena pyriformis; thus, it was indicated that the particles were undescribed cell organelles unrelated to mitochondria.

Hair transplantation is a surgical technique that moves individual hair follicles from a part of the body called the donor site to bald or balding part of the body known as the recipient site. It is primarily used to treat male pattern baldness. In this condition, grafts containing hair follicles that are genetically resistant to balding are transplanted to bald scalp. It is also used to restore eyelashes, eyebrows, beard hair, chest hair, and pubic hair and to fill in scars caused by accidents or surgery such as face-lifts and previous hair transplants. Hair transplantation differs from skin grafting in that grafts contain almost all of the epidermis and dermis surrounding the hair follicle, and many tiny grafts are transplanted rather than a single strip of skin. Since hair naturally grows in follicles in groups of 1 to 4 hairs, transplantation takes advantage of these naturally occurring follicular units. This achieves a more natural appearance by matching hair for hair through Follicular unit transplantation (FUT). Donor hair can be harvested in two different ways. Small grafts of naturally occurring units of one to four hairs, called follicular units, can be moved to balding areas of the hair restoration. These follicular units are surgically implanted in the scalp in very close proximity to one another and in large numbers.

Sources: en.wikipedia.org

Supporting material

== Function == Several lines of evidence suggest that PD-1 and its ligands negatively regulate immune responses. PD-1 knockout mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy on the C57BL/6 and BALB/c backgrounds, respectively. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. IFN-γ is a key pro-inflammatory cytokine that promotes T cell inflammatory activity. Reduced T cell proliferation was also correlated with attenuated IL-2 secretion and together, these data suggest that PD-1 negatively regulates T cell responses. Experiments using PD-L1 transfected DCs and PD-1 expressing transgenic (Tg) CD4+ and CD8+ T cells suggest that CD8+ T cells are more susceptible to inhibition by PD-L1, although this could be dependent on the strength of TCR signaling. Consistent with a role in negatively regulating CD8+ T cell responses, using an LCMV viral vector model of chronic infection, Rafi Ahmed's group showed that the PD-1-PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus specific CD8+ T cells, which can be reversed by blocking the PD-1-PD-L1 interaction. Expression of PD-L1 on tumor cells inhibits anti-tumor activity through engagement of PD-1 on effector T cells. Expression of PD-L1 on tumors is correlated with reduced survival in esophageal, pancreatic and other types of cancers, highlighting this pathway as a target for immunotherapy.

In Europe the field followed its own pathway; for example in Germany the parallel interventional society began to break free of the DR society in 2008. In the UK, interventional radiology was approved as a sub-specialty of clinical radiology in 2010. While many countries have an interventional radiology society, there is also the European-wide Cardiovascular and Interventional Radiological Society of Europe, whose aim is to support teaching, science, research and clinical practice in the field by hosting meetings, educational workshops and promoting patient safety initiatives. Furthermore, the Society provides an examination, the European Board of Interventional Radiology (EBIR), which is a highly valuable qualification in interventional radiology based on the European Curriculum and Syllabus for IR.

Further, the method lacks the capability to distinguish between positive and negative nonsynonymous substitutions. Some amino acids are chemically similar to one another, whereas other substitutions may place an amino acid with wildly different properties to its precursor. In most situations, a smaller chemical change is more likely to allow the protein to continue to function, and a large chemical change is likely to disrupt the chemical structure and cause the protein to malfunction. However, incorporating this into a model is not straightforward as the relationship between a nucleotide substitution and the effects of the modified chemical properties is very difficult to determine. An additional concern is that the effects of time must be incorporated into an analysis, if the lineages being compared are closely related; this is because it can take a number of generations for natural selection to "weed out" deleterious mutations from a population, especially if their effect on fitness is weak. This limits the usefulness of the Ka/Ks ratio for comparing closely related populations.

Sources: en.wikipedia.org

Frequently asked questions

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Why do two versions share one name?

The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.

What is the most reliable identifier?

The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network